18 research outputs found

    A typology of homicides: an investigation of Megargee's theory of control

    Get PDF
    In an attempt to explain why some mild mannered individuals commit extremely assaultive offences, Megargee (1966) has suggested that two personality types exist among extremely assaultive offenders, the undercontrolled who lack inhibitions against the expression of aggression and the overcontrolled who possess excessive inhibitions against such behaviour. Moderately assaultive offenders, however, are more likely to be composed soley of undercontrolled personalities according to Megargee's Theory of Control. The current study began by carrying out a cluster analysis of MMPI profiles of individuals convicted of homicide. Profile types remarkably similar to those obtained by Blackburn (l97l) from 'abnormal' homicides at Broadmoor were obtained which appeared to represent two broad categories of overcontrolled and undercontrolled individuals. A second cluster analysis of MMPI profiles from a random group of predominantly non-violent prisoners revealed, however, similar types. The results of a cluster analysis of WI profiles of non-criminals also challenged Megargee's theory as a profile type was produced which was similar to that found amongst extremely assaultive offenders, and which had previously been described as overcontrolled. The suggestion was made that 'controlled' was a more appropriate term than 'overcontrolled' and the validity of a controlled-undercontrolled typology was examined by contrasting controlled and undercontrolled homicides on a variety of background, intellectual, behavioural and attitudinal variables. In general support was found for the typology, particularly on prison oriented behavioural measures. The implications of the findings for the control and treatment of controlled and undercontrolled prisoners were discussed and a short MMPI scale which discriminated between these groups was developed, and tentatively named the Undercontrolled Personality Scale

    Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia

    Get PDF
    There is increasing clinical and molecular evidence for the role of hormones and specifically estrogen and its receptor in schizophrenia. A selective estrogen receptor modulator, raloxifene, stimulates estrogen-like activity in brain and can improve cognition in older adults. The present study tested the extent to which adjunctive raloxifene treatment improved cognition and reduced symptoms in young to middle-age men and women with schizophrenia. Ninety-eight patients with a diagnosis of schizophrenia or schizoaffective disorder were recruited into a dual-site, thirteen-week, randomized, double-blind, placebocontrolled, crossover trial of adjunctive raloxifene treatment in addition to their usual antipsychotic medications. Symptom severity and cognition in the domains of working memory, attention/processing speed, language and verbal memory were assessed at baseline, 6 and 13 weeks. Analyses of the initial 6-week phase of the study using a parallel groups design (with 39 patients receiving placebo and 40 receiving raloxifene) revealed that participants receiving adjunctive raloxifene treatment showed significant improvement relative to placebo in memory and attention/processing speed. There was no reduction in symptom severity with treatment compared with placebo. There were significant carryover effects, suggesting some cognitive benefits are sustained even after raloxifene withdrawal. Analysis of the 13-week crossover data revealed significant improvement with raloxifene only in attention/processing speed. This is the first study to show that daily, oral adjunctive raloxifene treatment at 120 mg per day has beneficial effects on attention/processing speed and memory for both men and women with schizophrenia. Thus, raloxifene may be useful as an adjunctive treatment for cognitive deficits associated with schizophrenia.TW Weickert, D Weinberg, R Lenroot, SV Catts, R Wells, A Vercammen, M O, Donnell, C Galletly, D Liu, R Balzan, B Short, D Pellen, J Curtis, VJ Carr, J Kulkarni, PR Schofield and CS Weicker

    Irish endocrine society

    No full text
    corecore